Work

PARP inhibitor–associated folate deficiency anemia

Year: 2026

Type: article

Abstract: Following PARPi initiation for BRCA1/2 -related malignancies, at least 3.1% of patients developed marked folate deficiency anemia, precipitating hemoglobin decreases from 11.1 (IQR 9.9-12.1) to 7.0 g/dL (IQR 6.3-7.4) ( P < 0.001), PRBC transfusion dependence (62.5%), and cancer treatment disruptions (75%).

Source: Blood Red Cells & Iron

DOI: 10.1016/j.brci.2026.100052

Authors: N. Rippel, D. I. Nathan, W. Fu, J. M. Liu, I. Shapira, P. Klein

Institutions: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,000